Actinium Pharmaceuticals (ATNM) Q4 2025 earnings summary

Executive summary

• Focused on developing targeted radiotherapies for oncology, with a pipeline including ATNM-400, Actimab-A, Iomab-B, and Iomab-ACT, addressing solid tumors and hematologic malignancies.

• No commercial revenue; operations funded primarily through equity sales and a $35M upfront licensing payment for Iomab-B in EUMENA.

• Net loss for 2025 was $33.9M, improved from $38.2M in 2024, driven by reduced R&D expenses and workforce optimization.

• Strategic focus on advancing ATNM-400 into clinical trials, expanding partnerships for late-stage hematology programs, and building internal manufacturing capabilities.

Financial highlights

• Total revenue for 2025 was $90K, all from grant revenue; no product sales.

• Research and development expenses decreased to $21.1M (from $30.0M in 2024), mainly due to lower CRO costs and headcount.

• General and administrative expenses increased to $15.2M (from $12.1M), primarily due to higher non-cash stock-based compensation.

• Net loss for 2025 was $33.9M, a $4.4M improvement over 2024.

• Cash and cash equivalents at year-end 2025 were $48.0M, with a full valuation allowance against $116.1M in deferred tax assets.

Outlook and guidance

• Existing resources expected to fund operations for more than 12 months from the report date.

• Plans to continue funding through equity sales and potential milestone/license payments.

• Strategic priorities include advancing ATNM-400, executing partnerships for Actimab-A and Iomab-B, and completing a cGMP manufacturing facility by late 2026.